FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved Merck's supplemental application for Isentress (raltegravir) to modify its labeling related to HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

SUPPL AP for ISENTRESS (RALTEGRAVIR)